Gursimran Kohli
Counsel
DelhiPractice Area
Sectors
I am a solution-oriented lawyer, who is passionate about providing practical advise to clients and help them achieve an optimal equilibrium between the regulatory requirements and commercial rationale. 9 years into the profession, I still take each day with utmost enthusiasm to bring my best to the table!
Gursimran Kohli is a part of the Delhi Office. Gursimran has over 9 years of experience with focus on M&A, Joint Ventures, Private Equity, Social Impact and Foundation, Regulatory Advisory, Corporate Governance and General Corporate Advisory. She has advised various foreign and domestic investors on their acquisitions and private equity investments (both equity and debt) in companies in India across a diverse range of industries and sectors, including retail and e-commerce, real estate, fintech, education, etc. Gursimran has also advised clients on successful exits of their investments from portfolio companies in India. She also regularly advises and assists foreign not-for-profit corporations and foundations on their entry in India and their activities, including grants and impact investments.
WORK HIGHLIGHTS
-
On its various joint venture, strategic investments and other M&A activities in India.
-
On its joint-venture with Brookfield for its commercial real estate assets in North India for a transaction value of USD 700 millon.
-
On (i) its acquisition of Sterling Biotech Limited under the liquidation process for an acquisition consideration of approx. INR 650 crores; and (ii) its joint-venture with Zydus for a transaction value of approx. INR 600 crores
-
On their entry in India, FCRA related matters and investments through debt, equity and blended finance structures.
-
On its acquisition of stake from its minority non-promoter shareholders and on capital reduction process involving an aggregate amount of approximately Rs. 1300 crores.
-
On its various investments in, and exits from India.
-
On its various joint venture, strategic investments and other M&A activities in India.
-
On its joint-venture with Brookfield for its commercial real estate assets in North India for a transaction value of USD 700 millon.
-
On (i) its acquisition of Sterling Biotech Limited under the liquidation process for an acquisition consideration of approx. INR 650 crores; and (ii) its joint-venture with Zydus for a transaction value of approx. INR 600 crores
-
On their entry in India, FCRA related matters and investments through debt, equity and blended finance structures.
-
On its acquisition of stake from its minority non-promoter shareholders and on capital reduction process involving an aggregate amount of approximately Rs. 1300 crores.
-
On its various investments in, and exits from India.
-
On its various joint venture, strategic investments and other M&A activities in India.
-
On its joint-venture with Brookfield for its commercial real estate assets in North India for a transaction value of USD 700 millon.
-
On (i) its acquisition of Sterling Biotech Limited under the liquidation process for an acquisition consideration of approx. INR 650 crores; and (ii) its joint-venture with Zydus for a transaction value of approx. INR 600 crores
-
On their entry in India, FCRA related matters and investments through debt, equity and blended finance structures.
-
On its acquisition of stake from its minority non-promoter shareholders and on capital reduction process involving an aggregate amount of approximately Rs. 1300 crores.
-
On its various investments in, and exits from India.
-
On its various joint venture, strategic investments and other M&A activities in India.
-
On its joint-venture with Brookfield for its commercial real estate assets in North India for a transaction value of USD 700 millon.
-
On (i) its acquisition of Sterling Biotech Limited under the liquidation process for an acquisition consideration of approx. INR 650 crores; and (ii) its joint-venture with Zydus for a transaction value of approx. INR 600 crores
-
On their entry in India, FCRA related matters and investments through debt, equity and blended finance structures.
-
On its acquisition of stake from its minority non-promoter shareholders and on capital reduction process involving an aggregate amount of approximately Rs. 1300 crores.
-
On its various investments in, and exits from India.
-
On its various joint venture, strategic investments and other M&A activities in India.
-
On its joint-venture with Brookfield for its commercial real estate assets in North India for a transaction value of USD 700 millon.
-
On (i) its acquisition of Sterling Biotech Limited under the liquidation process for an acquisition consideration of approx. INR 650 crores; and (ii) its joint-venture with Zydus for a transaction value of approx. INR 600 crores
-
On their entry in India, FCRA related matters and investments through debt, equity and blended finance structures.
-
On its acquisition of stake from its minority non-promoter shareholders and on capital reduction process involving an aggregate amount of approximately Rs. 1300 crores.
-
On its various investments in, and exits from India.
-
On its various joint venture, strategic investments and other M&A activities in India.
-
On its joint-venture with Brookfield for its commercial real estate assets in North India for a transaction value of USD 700 millon.
-
On (i) its acquisition of Sterling Biotech Limited under the liquidation process for an acquisition consideration of approx. INR 650 crores; and (ii) its joint-venture with Zydus for a transaction value of approx. INR 600 crores
-
On their entry in India, FCRA related matters and investments through debt, equity and blended finance structures.
-
On its acquisition of stake from its minority non-promoter shareholders and on capital reduction process involving an aggregate amount of approximately Rs. 1300 crores.
-
On its various investments in, and exits from India.
-
On its various joint venture, strategic investments and other M&A activities in India.
-
On its joint-venture with Brookfield for its commercial real estate assets in North India for a transaction value of USD 700 millon.
-
On (i) its acquisition of Sterling Biotech Limited under the liquidation process for an acquisition consideration of approx. INR 650 crores; and (ii) its joint-venture with Zydus for a transaction value of approx. INR 600 crores
-
On their entry in India, FCRA related matters and investments through debt, equity and blended finance structures.
-
On its acquisition of stake from its minority non-promoter shareholders and on capital reduction process involving an aggregate amount of approximately Rs. 1300 crores.
-
On its various investments in, and exits from India.
-
On its various joint venture, strategic investments and other M&A activities in India.
-
On its joint-venture with Brookfield for its commercial real estate assets in North India for a transaction value of USD 700 millon.
-
On (i) its acquisition of Sterling Biotech Limited under the liquidation process for an acquisition consideration of approx. INR 650 crores; and (ii) its joint-venture with Zydus for a transaction value of approx. INR 600 crores
-
On their entry in India, FCRA related matters and investments through debt, equity and blended finance structures.
-
On its acquisition of stake from its minority non-promoter shareholders and on capital reduction process involving an aggregate amount of approximately Rs. 1300 crores.
-
On its various investments in, and exits from India.
-
On its various joint venture, strategic investments and other M&A activities in India.
-
On its joint-venture with Brookfield for its commercial real estate assets in North India for a transaction value of USD 700 millon.
-
On (i) its acquisition of Sterling Biotech Limited under the liquidation process for an acquisition consideration of approx. INR 650 crores; and (ii) its joint-venture with Zydus for a transaction value of approx. INR 600 crores
-
On their entry in India, FCRA related matters and investments through debt, equity and blended finance structures.
-
On its acquisition of stake from its minority non-promoter shareholders and on capital reduction process involving an aggregate amount of approximately Rs. 1300 crores.
-
On its various investments in, and exits from India.
-
On its various joint venture, strategic investments and other M&A activities in India.
-
On its joint-venture with Brookfield for its commercial real estate assets in North India for a transaction value of USD 700 millon.
-
On (i) its acquisition of Sterling Biotech Limited under the liquidation process for an acquisition consideration of approx. INR 650 crores; and (ii) its joint-venture with Zydus for a transaction value of approx. INR 600 crores
-
On their entry in India, FCRA related matters and investments through debt, equity and blended finance structures.
-
On its acquisition of stake from its minority non-promoter shareholders and on capital reduction process involving an aggregate amount of approximately Rs. 1300 crores.
-
On its various investments in, and exits from India.
-
On its various joint venture, strategic investments and other M&A activities in India.
-
On its joint-venture with Brookfield for its commercial real estate assets in North India for a transaction value of USD 700 millon.
-
On (i) its acquisition of Sterling Biotech Limited under the liquidation process for an acquisition consideration of approx. INR 650 crores; and (ii) its joint-venture with Zydus for a transaction value of approx. INR 600 crores
-
On their entry in India, FCRA related matters and investments through debt, equity and blended finance structures.
-
On its acquisition of stake from its minority non-promoter shareholders and on capital reduction process involving an aggregate amount of approximately Rs. 1300 crores.
-
On its various investments in, and exits from India.